GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 9 Meters Biopharma Inc (OTCPK:NMTRQ) » Definitions » Cyclically Adjusted Price-to-FCF

9 Meters Biopharma (9 Meters Biopharma) Cyclically Adjusted Price-to-FCF : (As of May. 05, 2024)


View and export this data going back to 2016. Start your Free Trial

What is 9 Meters Biopharma Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


9 Meters Biopharma Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for 9 Meters Biopharma's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

9 Meters Biopharma Cyclically Adjusted Price-to-FCF Chart

9 Meters Biopharma Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

9 Meters Biopharma Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of 9 Meters Biopharma's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, 9 Meters Biopharma's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


9 Meters Biopharma's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 9 Meters Biopharma's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where 9 Meters Biopharma's Cyclically Adjusted Price-to-FCF falls into.



9 Meters Biopharma Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

9 Meters Biopharma's Cyclically Adjusted FCF per Share for the fiscal year that ended in Dec22 is calculated as:

For example, 9 Meters Biopharma's adjusted Free Cash Flow per Share data for the fiscal year that ended in Dec22 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec22 (Change)*Current CPI (Dec22)
=-2.875/125.2218*125.2218
=-2.875

Current CPI (Dec22) = 125.2218.

9 Meters Biopharma Annual Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201312 -143.407 98.326 -182.634
201412 -276.000 99.070 -348.858
201512 -64.074 99.792 -80.402
201612 -300.964 101.863 -369.981
201712 -8.646 104.011 -10.409
201812 -12.264 105.998 -14.488
201912 -10.792 108.420 -12.464
202012 -4.278 109.897 -4.875
202112 -2.631 117.630 -2.801
202212 -2.875 125.222 -2.875

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


9 Meters Biopharma  (OTCPK:NMTRQ) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


9 Meters Biopharma Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of 9 Meters Biopharma's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


9 Meters Biopharma (9 Meters Biopharma) Business Description

Traded in Other Exchanges
N/A
Address
4509 Creedmoor Road, Suite 201, Raleigh, NC, USA, 27612
9 Meters Biopharma Inc is a clinical-stage biopharmaceutical company focused on rare and unmet needs in gastroenterology. Its pipeline includes drug candidates for short bowel syndrome (SBS), celiac disease, and three early-stage candidates for undisclosed rare diseases and/or unmet needs. Its products include NM-002, Larazotide, NM-003, and others.
Executives
Bethany Sensenig officer: Chief Financial Officer C/O 9 METERS BIOPHARMA, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615
John Temperato director, officer: Chief Executive Officer C/O MELINTA THERAPEUTICS,INC., 300 GEORGE STREET, SUITE 301, NEW HAVEN CT 06511
Mark A Sirgo director C/O BIODELIVERY SCIENCES INTERNATIONAL, 801 CORPORATE CENTER DRIVE -SUITE 210, RALEIGH NC 27607
Michael T. Constantino director C/O 9 METERS BIOPHARMA, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615
Samantha Ventimiglia director C/O 9 METERS BIOPHARMA, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615
Edward J Sitar officer: Chief Financial Officer 39 FLAMING ARROW ROAD, MAHWAH NJ 07430
Orbimed Israel Biofund Gp Limited Partnership 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 1022-4629
Yehuda Michael Rice director 155 WALNUT STREET, ENGLEWOOD NJ 07631
Nissim Darvish director, 10 percent owner C/O INNOVATE BIOPHARMACEUTICALS, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615
Orbimed Israel Gp Ltd. 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022-4629
Sandeep Laumas director, officer: Executive Chairman 8480 HONEYCUTT RD, SUITE 200, RALEIGH NC 27615
Jay P. Madan director, officer: President 8480 HONEYCUTT RD, SUITE 200, RALEIGH NC 27615
Roy Proujansky director 144 PAU NEL DRIVE, LANDENBERG PA 19350
Christopher P. Prior director, officer: Chief Executive Officer 8480 HONEYCUTT RD, SUITE 200, RALEIGH NC 27615
June Sherie Almenoff officer: COO and Chief Medical Officer C/O BRAINSTORM CELL THERAPEUTICS INC., 1325 AVENUE OF AMERICAS 28TH FLOOR, NEW YORK NY 10019

9 Meters Biopharma (9 Meters Biopharma) Headlines

From GuruFocus

9 Meters Biopharma Announces 1-for-20 Reverse Stock Split

By ACCESSWIRE ACCESSWIRE 10-17-2022